#United States #New York #Levi & Korsinsky #BioAge Labs #BIOA

Levi & Korsinsky Announces Class Action for BioAge Labs, Inc. Shareholders

In a significant development for investors in BioAge Labs, Inc. (NASDAQ: BIOA), law firm Levi & Korsinsky, LLP, has officially announced the filing of a class action securities lawsuit on behalf of affected shareholders. This legal action emerges in the wake of troubling revelations concerning the company’s lead product candidate, azelaprag, which has sparked concerns about investor losses.

Understanding the Class Action Lawsuit

The class action aims to represent shareholders who purchased BioAge stock in connection with the company's initial public offering (IPO) held on or around September 26, 2024. The lawsuit's primary goal is to recover losses sustained by investors due to alleged securities fraud. Such legal steps are critical for providing a platform where affected investors can seek justice together, rather than on an individual basis.

Recent Controversies Leading to Legal Action

The backdrop of this lawsuit is particularly concerning. On December 6, 2024, BioAge announced a discontinuation of its ongoing STRIDES Phase 2 trial for azelaprag, citing significant safety concerns related to elevated liver transaminase levels in trial participants. This announcement came just months after the IPO, during which BioAge had positioned azelaprag as a promising candidate for patients undergoing obesity therapy with incretin drugs. The market was clearly taken aback by the news, as reflected by the sharp decline in BioAge's stock price—plummeting from $20.09 per share on December 6, 2024, to $4.65 per share the following day.

Shareholder Implications and Next Steps

For shareholders who have experienced losses due to BioAge’s actions or misrepresentation, the window to act is limited. Individuals must request the court to appoint them as lead plaintiffs by March 10, 2025, to take part in the proceedings formally. Interestingly, participation as a lead plaintiff is not a prerequisite for any shareholder who wishes to seek compensation. Thus, this presents an opportunity for collective action among those affected.

Levi & Korsinsky emphasizes that there are no upfront costs to shareholders participating in this class action. This is particularly beneficial as it democratizes access to legal recourse, ensuring that shareholders can pursue compensation for their losses without the fear of financial burdens during the litigation process.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a substantial reputation over the last two decades for securing significant settlements on behalf of aggrieved investors and navigating complex securities litigation. Their experienced team, consisting of more than 70 professionals, has garnered recognition in ISS Securities Class Action Services' Top 50 Report for their consistent performance in high-stakes class action lawsuits.

For potential clients wanting further information or to discuss their options, the firm encourages reaching out. Interested parties can directly contact Joseph E. Levi, Esq. at (212) 363-7500 or via email at [email protected] Leveraging their expertise and dedication, Levi & Korsinsky aims to support former BioAge shareholders during this tumultuous time.

In conclusion, as this lawsuit unfolds, it presents critical implications not only for BioAge Labs' future but also for the overall market sentiment towards biotech investments. Shareholders are urged to stay informed and consider their options within the timeline provided by the appropriate legal avenues.

For more detailed information and updates, please visit Levi & Korsinsky's official website.